Abstract
Introduction
The last three years has seen several major shifts in generics company
strategies. From 2006 to 2008 a period of high M&A activity was seen as many
companies sought to expand geographically and create the scale required to
compete with large pharmaceutical companies. Since the global financial crisis
the level of deals has declined due to the implications of restricted debt
markets and the need to reduce company debt.
The global financial crisis has also affected government debt and subsequently
healthcare cost containment has become a prominent issue. Many nations and in
particular the US is seeking to reduce healthcare costs through promotion of
generics and creating better approval pathways for biogenerics.
Key findings
- The unbranded pharmaceutical industry grew from $41,476m in 2007 to
$44,364m in 2008, a 7.0% annual growth.
- Teva took over the position of global generics leader showing impressive
growth of 24.0% and sales of $7,015m for 2008. The company gained considerable
market share particularly in the US.
- Latin America was the fastest growing region with a 2007-08 annual growth
rate of 28.7% and a 2004-08 CAGR of 36.8%. This was predominantly due to the
largest Latin American market, Brazil, which grew with a 2004-08 CAGR of 41.1%.
Key features of this report
- Evaluation of the unbranded generics market from 2004-08 in terms of sales.
- Country and region specific analysis of the generics market in terms of
sales.
- Therapy area analysis including company and product level breakdown by
sales.
- Identify trends in M&A strategies including case studies of major M&A
deals from 2005 onwards.
Use this report to
- Understand the generic pharmaceutical market dynamics.
- Learn about issues driving and resisting growth for generics companies.
- Gain insight into growth strategies employed by the Top 10 generics
players.
- Target geographic focus through detailed analysis of countries and regions.
- Be informed on growth driving and growth resisting therapy areas and
molecule types
Discover
- What effect has the global financial crisis had on the generics industry?
- What growth strategies have leading generics players utilised and how
effectively?
- How has M&A activity shaped the generics industry?
- Which therapy areas are providing the strongest growth for generics
companies?
| 
View Cart
